NCT05020678View on ClinicalTrials.gov

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2038

Conditions
Lymphoma, Non-HodgkinB-cell Acute Lymphoblastic LeukemiaLarge B-cell LymphomaMantle Cell LymphomaIndolent LymphomaWaldenstrom MacroglobulinemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaAggressive LymphomaLarge-cell Lymphoma
Interventions
BIOLOGICAL

NKX019

NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.

Trial Locations (6)

2010

St. Vincent's Hospital, Sydney

2050

Institute of Haematology, Royal Prince Alfred Hospital, Camperdown

3000

Peter MacCallum Cancer Center, Melbourne

4029

Royal Brisbane and Woman's Hospital, Brisbane

44195

The Cleveland Clinic Foundation, Cleveland

80218

Colorado Blood Cancer Institute, Denver

All Listed Sponsors
lead

Nkarta, Inc.

INDUSTRY